MX2017005461A - Formulacion de buprenorfina inyectable. - Google Patents
Formulacion de buprenorfina inyectable.Info
- Publication number
- MX2017005461A MX2017005461A MX2017005461A MX2017005461A MX2017005461A MX 2017005461 A MX2017005461 A MX 2017005461A MX 2017005461 A MX2017005461 A MX 2017005461A MX 2017005461 A MX2017005461 A MX 2017005461A MX 2017005461 A MX2017005461 A MX 2017005461A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- buprenorphine
- opioid
- liquid composition
- provides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 4
- 229960001736 buprenorphine Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000009115 maintenance therapy Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 201000005040 opiate dependence Diseases 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona una formulación líquida inyectable que comprende: a) una matriz de liberación controlada de lípidos que comprende al menos 50% de lípidos triacilo; b) al menos un oxígeno que contiene disolvente orgánico; c) por lo menos 16% en peso de al menos un agente activo seleccionado de buprenorfina y sales de la misma, calculado como base libre de buprenorfina. La invención proporciona además una composición de liberación controlada, formada por la administración de la composición líquida inyectable a un sujeto preferiblemente humano. La invención proporciona también un método de administración de buprenorfina a un sujeto que comprende inyectar la composición líquida y un método para el tratamiento del dolor, para terapia de mantenimiento de opioides o para el tratamiento de la dependencia de opioides por medio de desintoxicación y/o mantenimiento o para el tratamiento o profilaxis de los síntomas de abstinencia de opioides y/o abstinencia de la cocaína inyectando la composición líquida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1419091.2A GB201419091D0 (en) | 2014-10-27 | 2014-10-27 | Formulations |
| PCT/EP2015/074901 WO2016066655A1 (en) | 2014-10-27 | 2015-10-27 | Injectable buprenorphine formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017005461A true MX2017005461A (es) | 2018-01-17 |
| MX389333B MX389333B (es) | 2025-03-20 |
Family
ID=52103459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005461A MX389333B (es) | 2014-10-27 | 2015-10-27 | Formulacion de buprenorfina inyectable. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180015031A1 (es) |
| EP (1) | EP3212168A1 (es) |
| JP (1) | JP6768648B2 (es) |
| KR (2) | KR102541281B1 (es) |
| CN (1) | CN107205920B (es) |
| AU (1) | AU2015340661B2 (es) |
| BR (1) | BR112017008721A2 (es) |
| CA (1) | CA2964045C (es) |
| CL (1) | CL2017001024A1 (es) |
| EA (1) | EA033935B1 (es) |
| GB (1) | GB201419091D0 (es) |
| IL (1) | IL251413B2 (es) |
| MX (1) | MX389333B (es) |
| MY (1) | MY183540A (es) |
| SG (1) | SG11201703158WA (es) |
| TW (1) | TW201625250A (es) |
| WO (1) | WO2016066655A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3326613A1 (en) | 2012-07-26 | 2018-05-30 | Camurus AB | Opioid formulations |
| MX387722B (es) | 2012-07-26 | 2025-03-18 | Camurus Ab | Formulaciones de opioides. |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| SG11201703632WA (en) | 2014-11-07 | 2017-06-29 | Indivior Uk Ltd | Buprenorphine dosing regimens |
| WO2018060213A1 (en) | 2016-09-27 | 2018-04-05 | Camurus Ab | Formulations containing a somatostatin receptor agonist |
| MY196269A (en) * | 2016-09-13 | 2023-03-24 | Alar Pharmaceuticals Inc | Sustained-Release Buprenorphine Formulations |
| PL3512495T3 (pl) | 2016-09-15 | 2023-01-23 | Camurus Ab | Preparaty analogu prostacykliny |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| WO2023020608A1 (zh) * | 2021-08-20 | 2023-02-23 | 苏州恩华生物医药科技有限公司 | 一种包含塞纳布啡的药物组合物 |
| WO2025229403A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
| WO2025229402A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263760C (zh) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物 |
| ATE382050T1 (de) * | 2002-11-25 | 2008-01-15 | Chi Mei Foundation Medical Ct | Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel |
| ATE401054T1 (de) | 2004-06-04 | 2008-08-15 | Camurus Ab | Flüssige depotformulierungen |
| AU2009270695A1 (en) * | 2008-07-17 | 2010-01-21 | Ap Pharma | Methods for enhancing the stability of polyorthoesters and their formulations |
| GB2469792A (en) | 2009-04-23 | 2010-11-03 | Calvin John Ross | Oil-based pharmaceutical formulation for sublingual delivery |
| GB2481018B (en) * | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| EP3326613A1 (en) * | 2012-07-26 | 2018-05-30 | Camurus AB | Opioid formulations |
| CN103142458B (zh) | 2013-01-22 | 2015-09-09 | 莱普德制药有限公司 | 无成瘾性镇痛缓释递药系统的组方与制备方法 |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
-
2014
- 2014-10-27 GB GBGB1419091.2A patent/GB201419091D0/en not_active Ceased
-
2015
- 2015-10-27 TW TW104135322A patent/TW201625250A/zh unknown
- 2015-10-27 US US15/520,946 patent/US20180015031A1/en not_active Abandoned
- 2015-10-27 KR KR1020237008326A patent/KR102541281B1/ko active Active
- 2015-10-27 JP JP2017522663A patent/JP6768648B2/ja active Active
- 2015-10-27 CN CN201580059438.XA patent/CN107205920B/zh active Active
- 2015-10-27 CA CA2964045A patent/CA2964045C/en active Active
- 2015-10-27 SG SG11201703158WA patent/SG11201703158WA/en unknown
- 2015-10-27 BR BR112017008721A patent/BR112017008721A2/pt not_active Application Discontinuation
- 2015-10-27 AU AU2015340661A patent/AU2015340661B2/en active Active
- 2015-10-27 MX MX2017005461A patent/MX389333B/es unknown
- 2015-10-27 KR KR1020177011897A patent/KR20170072237A/ko not_active Ceased
- 2015-10-27 EA EA201790721A patent/EA033935B1/ru unknown
- 2015-10-27 EP EP15785136.1A patent/EP3212168A1/en active Pending
- 2015-10-27 WO PCT/EP2015/074901 patent/WO2016066655A1/en not_active Ceased
- 2015-10-27 MY MYPI2017000508A patent/MY183540A/en unknown
-
2017
- 2017-03-27 IL IL251413A patent/IL251413B2/en unknown
- 2017-04-25 CL CL2017001024A patent/CL2017001024A1/es unknown
-
2021
- 2021-04-20 US US17/234,989 patent/US12029813B2/en active Active
-
2024
- 2024-05-21 US US18/670,277 patent/US12396944B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12396944B2 (en) | 2025-08-26 |
| WO2016066655A1 (en) | 2016-05-06 |
| US12029813B2 (en) | 2024-07-09 |
| EA201790721A1 (ru) | 2017-09-29 |
| SG11201703158WA (en) | 2017-05-30 |
| IL251413B1 (en) | 2023-01-01 |
| KR102541281B1 (ko) | 2023-06-13 |
| KR20170072237A (ko) | 2017-06-26 |
| AU2015340661B2 (en) | 2018-04-26 |
| CN107205920A (zh) | 2017-09-26 |
| US20180015031A1 (en) | 2018-01-18 |
| TW201625250A (zh) | 2016-07-16 |
| CA2964045C (en) | 2023-03-07 |
| IL251413B2 (en) | 2023-05-01 |
| KR20230039767A (ko) | 2023-03-21 |
| NZ730521A (en) | 2023-11-24 |
| GB201419091D0 (en) | 2014-12-10 |
| EA033935B1 (ru) | 2019-12-11 |
| MX389333B (es) | 2025-03-20 |
| IL251413A0 (en) | 2017-05-29 |
| BR112017008721A2 (pt) | 2018-01-30 |
| CA2964045A1 (en) | 2016-05-06 |
| JP6768648B2 (ja) | 2020-10-14 |
| CL2017001024A1 (es) | 2017-11-10 |
| JP2017532354A (ja) | 2017-11-02 |
| EP3212168A1 (en) | 2017-09-06 |
| CN107205920B (zh) | 2021-05-25 |
| US20210308041A1 (en) | 2021-10-07 |
| US20250041205A1 (en) | 2025-02-06 |
| MY183540A (en) | 2021-02-25 |
| AU2015340661A1 (en) | 2017-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017005461A (es) | Formulacion de buprenorfina inyectable. | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| UY32874A (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
| MX2021014049A (es) | Compuestos espiro triciclicos. | |
| CO6300949A2 (es) | Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| CO7190238A2 (es) | Formulaciones de opioides | |
| UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2019001658A1 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. | |
| MX2016004530A (es) | Rapamicina para el tratamiento de linfangioleiomiomatosis. | |
| CY1124016T1 (el) | Φαρμακοτεχνικες μορφες οπιοειδων | |
| ECSP14013200A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| AR091706A1 (es) | Formulaciones de laquinimod sin agentes alcalinizantes | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
| MX2015005038A (es) | Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson. |